SOX9 is a key component of RUNX2-regulated transcriptional circuitry in osteosarcoma
Osteosarcoma (OS) is the most common bone cancer in children and adolescents. Although the 5-year survival rate of most OS is more than 70%, it drops to 25% for those with recurrent or metastasized tumors. Furthermore, the standard care of OS has not changed in the past three or more decades, and there is no FDA-approved targeted therapy and immunotherapy for OS. Therefore, there is a great need to develop new therapeutic targets to reduce side effects and improve the prognosis for OS patients. The lack of targetable genetic alterations in OS suggests that transcriptional and epigenetic events are involved in the etiology ...
Source: Videocast - All Events - September 5, 2023 Category: General Medicine Tags: Upcoming Events Source Type: video
INSPIRED Symposium: Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions
With the primary goal to bring together the expanding pediatric and young adult CAR T-cell community, in addressing major clinical advances achieved over the last decade and outstanding gaps warranting further focus, we aim to reflect on the 10+ year experience of CAR T-cell delivery to pediatric and young adults with B-cell malignancies. Based on experience gained over this time, this conference will focus on highlighting current best practices, opportunities to address unmet needs, and areas where future research is needed or ongoing. Our primary goal for this conference is to allow for cross-fertilization and collaborat...
Source: Videocast - All Events - February 23, 2023 Category: General Medicine Tags: Upcoming Events Source Type: video
Pathways to Prevention Workshop: Methods for Evaluating Natural Experiments in Obesity (Day 2)
Obesity is a major contributor to serious health conditions in children and adults. The prevalence of obesity in the United States and globally has grown rapidly in the last three decades; thus, there is a pressing need to help people achieve and maintain a healthy weight.
Obesity is commonly defined as having a body mass index (BMI) greater than or equal to 30. In 2014, more than one-third (37.7%) of U.S. adults (Flegal, 2016 ) and 17% of U.S. children and young adults under the age of 20 (Ogden, 2016 ) met this definition, accounting for about 55% of the total U.S. population. There are also persistent disparities among ...
Source: Videocast - All Events - May 2, 2017 Category: Journals (General) Tags: Upcoming Events Source Type: video
Pathways to Prevention Workshop: Methods for Evaluating Natural Experiments in Obesity (Day 1)
Obesity is a major contributor to serious health conditions in children and adults. The prevalence of obesity in the United States and globally has grown rapidly in the last three decades; thus, there is a pressing need to help people achieve and maintain a healthy weight.
Obesity is commonly defined as having a body mass index (BMI) greater than or equal to 30. In 2014, more than one-third (37.7%) of U.S. adults (Flegal, 2016 ) and 17% of U.S. children and young adults under the age of 20 (Ogden, 2016 ) met this definition, accounting for about 55% of the total U.S. population. There are also persistent disparities among ...
Source: Videocast - All Events - May 2, 2017 Category: Journals (General) Tags: Upcoming Events Source Type: video
1) Lentivector Gene Therapy for X-linked Severe Combined Immune Deficiency (XSCID) in Older Children, Young Adults with Impaired Immunity 2) A New Approach to Cancer Immunotherapy Targeting Unique Cancer Mutations
Presented by: Harry L. Malech, Chief, Laboratory of Host Defenses and Chief, Genetic Immunotherapy Section, NIAID, NIH and Steven A. Rosenberg, MD, PhD, Chief, Surgery Branch, NCI, NIHCategory: Clinical Center Grand RoundsAired date: 09/30/2015 (Source: Videocast - All Events)
Source: Videocast - All Events - October 1, 2015 Category: Journals (General) Tags: Past Events Source Type: video
1) Lentivector Gene Therapy for X-linked Severe Combined Immune Deficiency (XSCID) in Older Children, Young Adults with Impaired Immunity 2) A New Approach to Cancer Immunotherapy Targeting Unique Cancer Mutations
Lentivector Gene Therapy for X-linked Severe Combined Immune Deficiency (XSCID) in Older Children, Young Adults with Impaired Immunity and Recurrent Infections Despite Prior Haplo-transplant
Harry L. Malech, MD
Chief, Laboratory of Host Defenses and
Chief, Genetic Immunotherapy Section, NIAID
A New Approach to Cancer Immunotherapy Targeting Unique Cancer Mutations
Steven A. Rosenberg, MD, PhD
Chief, Surgery Branch, NCI
For more information go to http://www.cc.nih.gov/about/news/grcurrent.htmlAir date: 9/30/2015 12:00:00 PM (Source: Videocast - All Events)
Source: Videocast - All Events - September 1, 2015 Category: Journals (General) Tags: Upcoming Events Source Type: video
Childhood and Adolescent Nutrition and Growth Drive Breast Cancer Risk: Untapped Opportunities for Prevention
Presented by: Graham Colditz, MD, DrPH, Alvin J. Siteman Cancer Center, Washington University School of MedicineCategory: Stars in NutritionAired date: 10/06/2014 (Source: Videocast - All Events)
Source: Videocast - All Events - October 7, 2014 Category: Journals (General) Tags: Past Events Source Type: video
